Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

T. Munir, C. Moreno, C. Owen, G. Follows, O. Benjamini, A. Janssens, MD. Levin, A. Osterborg, T. Robak, M. Simkovic, D. Stevens, S. Voloshin, V. Vorobyev, M. Yagci, L. Ysebaert, K. Qi, Q. Qi, L. Parisi, S. Srinivasan, N. Schuier, K. Baeten, A....

. 2023 ; 41 (21) : 3689-3699. [pub] 20230606

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016853

PURPOSE: In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment. METHODS: Undetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10-4) and <1 CLL cell per 100,000 (<10-5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3). RESULTS: Ibrutinib + venetoclax achieved deeper uMRD (<10-5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10-5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10-4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10-4) and dMRD (≥10-4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM. CONCLUSION: Molecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for patients not achieving uMRD (<10-4), PFS rates remained high with ibrutinib + venetoclax; this is a novel finding and requires additional follow-up to confirm its persistence over time.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016853
003      
CZ-PrNML
005      
20231026105516.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.22.02283 $2 doi
035    __
$a (PubMed)37279408
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Munir, Talha $u St James's Hospital, Leeds, United Kingdom $1 https://orcid.org/0000000229010769
245    10
$a Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / $c T. Munir, C. Moreno, C. Owen, G. Follows, O. Benjamini, A. Janssens, MD. Levin, A. Osterborg, T. Robak, M. Simkovic, D. Stevens, S. Voloshin, V. Vorobyev, M. Yagci, L. Ysebaert, K. Qi, Q. Qi, L. Parisi, S. Srinivasan, N. Schuier, K. Baeten, A. Howes, DB. Caces, CU. Niemann, AP. Kater
520    9_
$a PURPOSE: In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment. METHODS: Undetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10-4) and <1 CLL cell per 100,000 (<10-5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3). RESULTS: Ibrutinib + venetoclax achieved deeper uMRD (<10-5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10-5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10-4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10-4) and dMRD (≥10-4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM. CONCLUSION: Molecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for patients not achieving uMRD (<10-4), PFS rates remained high with ibrutinib + venetoclax; this is a novel finding and requires additional follow-up to confirm its persistence over time.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    12
$a chronická lymfatická leukemie $x farmakoterapie $7 D015451
650    _2
$a reziduální nádor $x farmakoterapie $7 D018365
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a bicyklické sloučeniny heterocyklické $x škodlivé účinky $7 D019086
650    _2
$a chlorambucil $x škodlivé účinky $7 D002699
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Moreno, Carol $u Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Research Leukaemia Research Institute, Barcelona, Spain
700    1_
$a Owen, Carolyn $u Tom Baker Cancer Centre, Calgary, Canada
700    1_
$a Follows, George $u Addenbrookes Hospital, Cambridge, United Kingdom
700    1_
$a Benjamini, Ohad $u Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Janssens, Ann $u UZ Leuven Gasthuisberg, Leuven, Belgium
700    1_
$a Levin, Mark-David $u Albert Schweitzer Hospital, Dordrecht, the Netherlands $1 https://orcid.org/0000000321393547
700    1_
$a Osterborg, Anders $u Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Robak, Tadeusz $u Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland $1 https://orcid.org/0000000234116357
700    1_
$a Simkovic, Martin $u University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000303315334 $7 xx0117538
700    1_
$a Stevens, Don $u Norton Cancer Institute, Louisville, KY
700    1_
$a Voloshin, Sergey $u Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia
700    1_
$a Vorobyev, Vladimir $u S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia $1 https://orcid.org/0000000226928961
700    1_
$a Yagci, Munci $u Gazi Universitesi Tip Fakultesi, Ankara, Turkey
700    1_
$a Ysebaert, Loic $u Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France $1 https://orcid.org/0000000341027261
700    1_
$a Qi, Keqin $u Janssen Research & Development, Titusville, NJ $1 https://orcid.org/0000000289422888
700    1_
$a Qi, Qianya $u Janssen Research & Development, Raritan, NJ
700    1_
$a Parisi, Lori $u Janssen Research & Development, Raritan, NJ
700    1_
$a Srinivasan, Srimathi $u Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA $1 https://orcid.org/0000000172029425
700    1_
$a Schuier, Natasha $u Janssen Research & Development, Düsseldorf, Germany
700    1_
$a Baeten, Kurt $u Janssen Research & Development, Beerse, Belgium
700    1_
$a Howes, Angela $u Janssen Research & Development, High Wycombe, United Kingdom
700    1_
$a Caces, Donne Bennett $u Janssen Research & Development, Raritan, NJ
700    1_
$a Niemann, Carsten U $u Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark $1 https://orcid.org/0000000198805242
700    1_
$a Kater, Arnon P $u Amsterdam Medical Centers, University of Amsterdam, Amsterdam, the Netherlands $1 https://orcid.org/0000000331901891
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 21 (2023), s. 3689-3699
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37279408 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105510 $b ABA008
999    __
$a ok $b bmc $g 2000403 $s 1203215
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 21 $d 3689-3699 $e 20230606 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace